200,033 Shares in Takeda Pharmaceutical Co. $TAK Acquired by XY Capital Ltd

XY Capital Ltd bought a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 200,033 shares of the company’s stock, valued at approximately $2,928,000. Takeda Pharmaceutical comprises 1.5% of XY Capital Ltd’s investment portfolio, making the stock its 14th biggest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of TAK. Glenmede Investment Management LP increased its holdings in shares of Takeda Pharmaceutical by 12.4% in the 3rd quarter. Glenmede Investment Management LP now owns 34,677 shares of the company’s stock worth $508,000 after buying an additional 3,824 shares during the last quarter. Pathstone Holdings LLC lifted its holdings in shares of Takeda Pharmaceutical by 7.4% during the 3rd quarter. Pathstone Holdings LLC now owns 238,338 shares of the company’s stock worth $3,489,000 after acquiring an additional 16,486 shares during the last quarter. Boston Partners grew its position in Takeda Pharmaceutical by 11.6% in the third quarter. Boston Partners now owns 117,954 shares of the company’s stock worth $1,727,000 after acquiring an additional 12,219 shares in the last quarter. Entropy Technologies LP bought a new position in Takeda Pharmaceutical in the third quarter valued at $309,000. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Takeda Pharmaceutical by 132.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after purchasing an additional 1,610,088 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.1%

NYSE TAK opened at $17.76 on Friday. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.82. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average of $17.44 and a 200-day moving average of $15.55. The firm has a market cap of $56.50 billion, a PE ratio of 73.98 and a beta of 0.01.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.40. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.The company had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $7.81 billion. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Morgan Stanley began coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating for the company. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.